CYTOKINETICS INC 4

EVP Research & Development Fady Ibraham Malik exercised 3,500 stock options at $7.80 and sold 3,500 Cytokinetics Inc. common shares at $80.59 on July 21, 2026.

On July 21, 2026, Cytokinetics Inc. EVP of Research & Development, Dr. Fady Ibraham Malik, exercised 3,500 non-qualified stock options at an exercise price of $7.80 per share, acquiring 3,500 shares of common stock, and on the same day sold 3,500 shares of common stock at $80.59 per share in an apparent cashless or sell-to-cover style transaction. The option exercise added 3,500 shares to his direct holdings, bringing them to 157,402 shares immediately after the exercise, and the subsequent sale reduced his direct ownership to 153,902 shares. The aggregate option exercise cost was approximately $27,300, while the gross proceeds from the sale were approximately $282,065, indicating that the activity was likely driven by liquidity or diversification rather than a directional change in his long-term ownership, as his resulting stake in the company remains significant at roughly 153,902 shares.

Filing Facts

CIK

1061983

Ticker

CYTK

Form

4

Source Type

fda

Accession

0001061983-26-000084

Alert Tier

6